Trizzino John, who is SVP, Commercial Operations at Novavax, Inc. (NASDAQ:NVAX), bought 16,500 shares at $4.51 on June 17, 2014. Following this transaction, the SVP, Commercial Operations owned 16,500 shares meaning that the stake was boosted by 100% with the 16,500-share transaction. Novavax, Inc. (NASDAQ:NVAX) weekly performance is 6.30%. On last trading day company shares ended up $4.89. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX) distance from 50-day simple moving average (SMA50) is 11.98%.
Insys Therapeutics (NASDAQ:INSY) Director John N. Kapoor bought 5,000 shares of Insys Therapeutics stock in a transaction dated Monday, June 16th. The stock was purchased at an average cost of $26.13 per share, with a total value of $130,650.00. Following the completion of the transaction, the director now directly owns 15,991 shares of the company’s stock, valued at approximately $417,845. Insys Therapeutics Inc (NASDAQ:INSY) shares advanced 1.23% in last trading session and ended the day on $29.52. INSY Gross Margin is 87.90% and its return on assets is 56.80%. Insys Therapeutics Inc (NASDAQ:INSY) quarterly performance is -34.95%.
BioTime (NYSE:BTX) Director Broadwood Partners Lp bought 1,000,000 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $2,500,000.00. BioTime, Inc. (NYSEMKT:BTX) shares moved down -0.92% in last trading session and was closed at $3.22, while trading in range of $3.18 – $3.31. BioTime, Inc. (NYSEMKT:BTX) year to date (YTD) performance is -10.56%.
OvaScience Inc (NASDAQ:OVAS)’s director Richard Aldrich purchased 2,000 shares of OVAS in a transaction dated on June 16, 2014. OvaScience Inc (NASDAQ:OVAS) shares were purchased at an average price of $8.52 for total worth of $17,040.00. OvaScience Inc (NASDAQ:OVAS) ended the last trading day at $8.74. Company weekly volatility is calculated as 8.59% and price to cash ratio as 2.37.
ImmuCell Corporation (NASDAQ:ICCC)’s director Jonathan E Rothschild purchased 5,901 shares of ICCC in a transaction dated on June 16, 2014. ImmuCell Corporation (NASDAQ:ICCC) shares were purchased at an average price of $4.57 for total worth of $26,967.57. ImmuCell Corporation (NASDAQ:ICCC) shares moved down -4.12% in last trading session and was closed at $4.65, while trading in range of $4.65 – $4.65. ImmuCell Corporation (NASDAQ:ICCC) year to date (YTD) performance is 8.90%.